ENTXEntera Bio Ltd.
- GlobeNewswire
Entera Announces Second Quarter 2026 Financial Results and Business Updates
U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis ...
- GlobeNewswire
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 ...
- GlobeNewswire
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
TEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief Executive ...
- PR Newswire
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its... ...
- GlobeNewswire
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first ...
- GlobeNewswire
Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market
Entera Bio (NASDAQ:ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, creating a clear ...
- GlobeNewswire
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug ...
- GlobeNewswire
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, ...
- GlobeNewswire
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a ...
- GlobeNewswire
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide ...
- GlobeNewswire
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Entera Bio, Lowers Price Target to $9
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entera Bio with a Buy and lowers the price target from $10 to $9. ...
- GlobeNewswire
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (NASDAQ:ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment ...
- GlobeNewswire
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced it will ...
- PR Newswire
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the... ...
- GlobeNewswire
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a securities ...
- GlobeNewswire
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early ...
- GlobeNewswire
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 ...
- GlobeNewswire
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that ...
- GlobeNewswire
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that ...
- GlobeNewswire
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that ...
- GlobeNewswire
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an ...
- GlobeNewswire
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 ...
- GlobeNewswire
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores ...
- GlobeNewswire
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in ...